- Following TGA approval, NSW Health to Implement PixCell's HemoScreen(TM) 
Device Across Health System

    PixCell Medical (https://www.pixcell-medical.com/), innovator of rapid 
diagnostic solutions at the point-of-care, announced today that NSW 
(https://www.health.nsw.gov.au/Pages/default.aspx) Health Pathology, the 
provider of public pathology services for the New South Wales (NSW) government, 
will deploy PixCell's HemoScreen(TM) hematology analyzer for rapid, 
lab-accurate Complete Blood Count (CBC) testing, accessible at the point of 
care.

    PixCell has worked closely with NSW Health Pathology over the past year to 
evaluate the HemoScreen(TM) and they are now in the position to pioneer the use 
of this innovative POCT technology in facilities across the state.

    HemoScreen™ will enable true point-of-care testing (POCT) in terms of 
operation, electronic result delivery through an Internet of Things approach, 
ease-of-use, and transportability, while still providing core lab quality 
results. Outside of Sweden and Denmark, Australia will be the first country to 
get HemoScreen(TM) devices, which will soon be implemented throughout NSW.

     The collaboration includes the installation of a large number of 
HemoScreen(TM) devices that provide the full 5-part differential CBC test with 
comprehensive abnormal cell flagging. In this initial deployment, NSW Health 
Pathology will implement HemoScreen(TM) devices within small labs, in large 
emergency departments without onsite labs, and to upgrade some existing 
technology. The devices will then be further assessed for utility in oncology 
clinics and other settings.

    "We recognize the need to simplify real-time blood testing and are proud to 
work with NSW Health Pathology to increase accessibility to POC diagnostics," 
said Avishay Bransky, Ph.D., CEO and co-founder of PixCell Medical. 
"HemoScreen(TM) delivers accurate readings of 20 standard blood count 
parameters, which are routinely used to check the overall health status of a 
patient. The CBC has recently found valid to monitor the severity of COVID-19 
and the progression of the disease."

    POCD Scientific (https://www.pocdscientific.com.au/), boasting over 125 
years of experience in the supply and use of scientific equipment and products, 
will be the sole distributor of HemoScreens for the region of Australia.
    This news follows PixCell's recent approval from the TGA.

    About PixCell Medical

    PixCell Medical provides the first truly portable point-of-care blood 
diagnostic solution. Leveraging the company's patented Viscoelastic Focusing 
technology, along with AI-powered machine vision, PixCell's FDA-cleared and 
CE-approved HemoScreen diagnostic platform shortens diagnostic results delivery 
from days to minutes. With just one drop of blood and within six minutes, 
PixCell delivers accurate readings of 20 standard blood count parameters, 
saving patients, clinicians and health systems significant time and costs.

    For more information: www.pixcell-medical.com and follow PixCell on 
LinkedIn (https://www.linkedin.com/company/pixcell-medical-technologies/).

    Media Contact:
    Finn Partners for PixCell Medical
    Lior Feigin
    lior.feigin@finnpartners.com
    @LiorFeigin

    Source: PixCell Medical